BioSpace12h
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical ...
BioSpace12h
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...
BioSpace12h
Amylin Commands Weight-Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
BioSpace10h
Lilly Claims Key Weight Loss Victory Over Novo in Head-to-Head Study
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...
BioSpace9h
Trump Administration a Mixed Bag for Biopharma
President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.
BioSpace12h
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...